Bexarotene benefits a subset of patients with NSCLC

23 April 2008 Print this article Comments Share this article
Results of the SPIRIT II trial show that high-grade hypertriglyceridaemia in patients treated with bexarotene, as part of first-line therapy in patients with NSCLC, is correlated with increased survival....

Want to read complete article? Please Sign in or Register.

Most viewed articles this week

Recent comments

Related sites